Back to top
more

Journey Medical (DERM)

(Delayed Data from NSDQ)

$5.40 USD

5.40
7,091

-0.06 (-1.10%)

Updated Jul 22, 2024 01:42 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (146 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Pfizer's (PFE) Multiple Myeloma Drug Elrexfio Gets Nod in EU

by Zacks Equity Research

Pfizer's (PFE) targeted immunotherapy, Elrexfio, for treating heavily pretreated adults with relapsed/refractory multiple myeloma gets EC's conditional marketing authorization.

Merck's (MRK) Keytruda, Lenvima Endometrial Cancer Study Fails

by Zacks Equity Research

The combination of Merck's (MRK) Keytruda and Eisai's Lenvima for the first-line treatment of advanced/recurrent endometrial carcinoma fails to meet dual primary endpoints in late-stage study.

Kinjel Shah headshot

5 Small Drug Stocks to Buy on Hopes of Better Prospects in the New Year

by Kinjel Shah

Innovation is expected to continue driving growth in the Medical-Drugs industry. DERM, LYRA, AUPH, ALPN and HARP may prove to be good additions to one's portfolio.

Nilanjan Choudhury headshot

Relative Price Strength Makes These 5 Stocks Excellent Buys

by Nilanjan Choudhury

WING, JAKK, NSIT, GIII and DERM are five stocks with explosive relative price strength.

The Zacks Analyst Blog Highlights Beacon Roofing Supply, TopBuild, Journey Medical, and Shift4

by Zacks Equity Research

Beacon Roofing Supply, TopBuild, Journey Medical, and Shift4 are included in this Analyst Blog.

Journey Medical (DERM) Up on Update for Skin Disease Candidate

by Zacks Equity Research

Journey Medical (DERM) plans to submit a new drug application (NDA) to the FDA for DFD-29 to treat rosacea in adults by 2023-end. Stock rises.

Tirthankar Chakraborty headshot

4 Growth Stocks to Buy Ahead of a Strong Year-End Rally

by Tirthankar Chakraborty

With the Fed likely to trim interest rates along with seasonal tailwinds, growth stocks like Beacon Roofing Supply (BECN), TopBuild (BLD), Journey Medical (DERM) and Shift4 Payments (FOUR) are poised to gain strength.

Are You Looking for a Top Momentum Pick? Why Journey Medical Corporation (DERM) is a Great Choice

by Zacks Equity Research

Does Journey Medical Corporation (DERM) have what it takes to be a top stock pick for momentum investors? Let's find out.

What Makes Journey Medical Corporation (DERM) a Good Fit for 'Trend Investing'

by Zacks Equity Research

Journey Medical Corporation (DERM) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Is Corvus Pharmaceuticals (CRVS) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Corvus Pharmaceuticals (CRVS) and Journey Medical Corporation (DERM) have performed compared to their sector so far this year.

Journey Medical (DERM) & Maruho Ink Deal for Qbrexza Asia Rights

by Zacks Equity Research

Journey Medical (DERM) enters into a second licensing agreement with Maruho to develop and commercialize Qbrexza to treat hyperhidrosis in certain Asian countries. The stock surges 18.4%.

Journey Medical Corporation (DERM) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Journey Medical Corporation (DERM) delivered earnings and revenue surprises of -35.29% and 15.95%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Assertio (ASRT) Q2 Earnings Miss Estimates

by Zacks Equity Research

Assertio (ASRT) delivered earnings and revenue surprises of -7.14% and 3.57%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

United Therapeutics (UTHR) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

United Therapeutics (UTHR) delivered earnings and revenue surprises of 18.82% and 12.06%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Journey Medical (DERM) to Post Skin Disease Data, Stock Rises 26%

by Zacks Equity Research

Journey Medical (DERM) rises 26% on Monday after announcing the tentative date for reporting top-line results from its late-stage studies evaluating DFD-29 in treating papulopustular rosacea.

Biotech Stock Roundup: KDNY Up on NVS Buyout, BIIB & Eisai's AD Drug Update & More

by Zacks Equity Research

Acquisition and regulatory updates from Chinook Therapeutics (KDNY) and Biogen (BIIB) are in focus in the biotech sector.

Journey Medical (DERM) Up on Rosacea Candidate's Positive Data

by Zacks Equity Research

Journey Medical's (DERM) phase I study, assessing the impact of DFD-29 on the microbial flora of healthy adults, obtains its primary endpoints.

Journey Medical Corporation (DERM) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Journey Medical Corporation (DERM) delivered earnings and revenue surprises of -29.55% and 23.02%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Journey Medical Corporation (DERM) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Journey Medical Corporation (DERM) delivered earnings and revenue surprises of -62.16% and 4.20%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Infinity Pharmaceuticals (INFI) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Infinity (INFI) delivered earnings and revenue surprises of 8.33% and 95.43%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Journey Medical Corporation (DERM) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Journey Medical Corporation (DERM) delivered earnings and revenue surprises of -67.65% and 11.59%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Journey Medical Corporation (DERM) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Journey Medical Corporation (DERM) delivered earnings and revenue surprises of -72% and 13.97%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Sigilon Therapeutics, Inc. (SGTX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Sigilon Therapeutics, Inc. (SGTX) delivered earnings and revenue surprises of 4.35% and 22.68%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Molecular Templates Inc. (MTEM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Molecular Templates Inc. (MTEM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Journey Medical Corporation (DERM) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

by Zacks Equity Research

After losing some value lately, a hammer chart pattern has been formed for Journey Medical Corporation (DERM), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.